Award
National Cancer Institute 5P01CA163205-13
Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.
Recipient
Brigham and Women's Hospital, Boston, MA, United States
Award Amount
$335,203.00
Ceiling
$335,203.00
Awarded
August 15, 2025
Identifier
5P01CA163205-13
This award funds research to develop an innovative oHSV-based immunotherapy for glioblastoma by enhancing immune cell trafficking and activation using engineered viruses with immune-modulating payloads, aiming to improve treatment efficacy and patient outcomes.
Description
Develop a novel, effective, and safe oncolytic herpes simplex viral (oHSV)-based immunotherapy for glioblastoma (GBM) by arming oHSVs with immune-modulation payloads to enhance anti-tumor immune responses and create a pro-inflammatory tumor microenvironment.